Contact Information: Contacts: Rama Modali President BioServe 301-470-3362 Rmodali[at]bioserve.com Constantine Theodoropulos BasePair Communications 617-816-4637 Constantine[at]basepaircomm.com
Fairbanks Institute Selects BioServe for Indiana Health Study of Type 2 Diabetes
| Source: BioServe
BELTSVILLE, MD--(Marketwire - August 26, 2009) - BioServe, a leading provider of clinical
bio-samples and research services, today announced that it has been
selected by the Fairbanks Institute for Healthy Communities to process all
biological samples for its landmark longitudinal study of type 2 diabetes.
This is the second phase of The Indiana Health Study, a community-based
research initiative using the population of Central Indiana as study
participants to create a research platform that will lead to the
development of new drugs and diagnostics for chronic diseases such as heart
disease, cancer and diabetes. BioServe is currently processing samples for
the first study of coronary artery disease that commenced in 2008.
"We initially chose BioServe to process all patient samples for our
coronary artery disease study based on the company's excellent reputation,
experience and ability to perform the processing under GLP conditions,"
said Cynthia Helphingstine, PhD, President and CEO, The Fairbanks
Institute. "Extending our relationship with BioServe for this important
second phase study on type 2 diabetes was an easy decision. BioServe
continues to demonstrate their proficiency at processing the many different
types of biological materials researchers need to get at the genetic,
lifestyle and environmental determinants of chronic disease that will one
day result in better ways to prevent and treat disease."
The Fairbanks Institute is on the cutting edge of a growing effort to
provide medical researchers with biological samples connected to detailed
longitudinal clinical information for many types of research studies. The
type 2 diabetes study is enrolling 500 people in Central Indiana with the
disease, and 500 people matched by gender, ethnicity and age but without
type 2 diabetes or its risk factors, such as elevated BP and abnormal lipid
profiles. People enrolled in the study will provide blood, urine and health
information (epigenetic, demographic and clinical information) at
enrollment and again at the two and five year points. Prospective clinical
information on study participants will be obtained through the Indiana
Network for Patient Care, a regional health information exchange that
connects the five major health systems in Indianapolis, and includes over
100 hospitals, surgery centers and clinics.
Rama Modali, President, BioServe, stated, "We are excited to continue to be
working with The Fairbanks Institute to further understanding of the
dynamics between chronic diseases, genetic polymorphisms and environmental
risk factors that increase the risk of disease."
About Fairbanks Institute
Formed with a $10 million gift from the Richard M. Fairbanks Foundation and
the collaboration of BioCrossroads, Indiana University School of Medicine,
Regenstrief Institute and other Indianapolis community health leaders,
Fairbanks Institute is creating one of the nation's most comprehensive
resources for finding better ways to prevent, diagnose and treat the
nation's most common, chronic diseases. Through the Indiana Health Study,
the Fairbanks Institute is assembling and maintaining a collection of
biological samples and linked clinical and disease-specific information
collected from the population of Indianapolis for academic and commercial
research use.
About BioServe
BioServe provides pharmaceutical, biotechnology, clinical and academic
research markets with comprehensive 'biomaterial to validated data' genomic
research services that generate pre-clinical data needed for breakthroughs
in drug discovery and molecular diagnostics. BioServe's services feature
over 600,000 high quality, well-annotated and clinically relevant
biological specimens from its Global Repository® and a suite of
complimentary CLIA-certified genomic research services. Used together or
separately BioServe's genomic services enable biomedical researchers to
efficiently conduct genomic and proteomic research, validate drug and
diagnostic targets and correlate clinical data with molecular data for the
development of improved drugs and diagnostics. BioServe has headquarters
in Beltsville, MD and Hyderabad, India. For more information please visit
www.bioserve.com or call 301-470-3362.